Evidence-Based Reviews

How to control weight gain when prescribing antidepressants

Author and Disclosure Information

 

References

Discussing with your patient the possibility of changing or worsening depressive symptoms when adding or switching medications allows them to be aware and engaged in the process and can encourage them to notice and report changes. Developing a sensible schedule to taper an existing medication slowly over several weeks and allowing a new one to build up gradually to a therapeutic level can help minimize adverse effects or a discontinuation syndrome.

If switching antidepressants is not possible, or is ineffective, an anti-obesity medication (Table 122-29) can be considered. These medications should not be considered first-line in weight loss management, but reserved for more difficult or refractory weight loss challenges and in patients who are not able to participate in weight loss or dieting programs because of cognitive disorders, a history of nonadherance, financial or travel limitations, or in those with poor social support systems such as homelessness.


Some of these medications are not reimbursed by insurance companies; therefore, consider the financial burden to the patient and their capacity for adherence to therapy, and discuss this challenge before initiating treatment. There is some evidence for using medications off-label to treat obesity (Table 2,30-34).


Anti-obesity medications typically are considered for patients with a BMI >30 or in any overweight patient with diabetes, hyperlipidemia, or cardiovascular disease. As always, discuss with patients and their primary care provider the potential benefits and risks of adding any of these or other medications to an existing treatment regimen.

If weight loss goals are not met, consider discontinuing anti-obesity therapy. Patients and physicians should be cognizant of the need to continue long-term maintenance on these medications after successful treatment—perhaps indefinitely, because patients frequently regain weight after medication is discontinued.

Bottom Line
Many antidepressants are known to increase the risk of excessive weight gain, although risk of weigh gain varies among antidepressant classes. First, advise changes in diet and exercise; next, initiate psychotherapy as indicated, and then consider referral to a nutritionist. Consider switching to an antidepressant with less potential for causing weight gain or adding bupropion, which could lead to weight loss, if your patient can tolerate it. If these strategies are unsuccessful, consider an anti-obesity medication.

Related Resource

Drug Brand Names
Amitriptyline • Elavil
Bupropion • Wellbutrin, Zybanr
Clomipramine • Anafranil
Desipramine • Norpramin
Exenatide • Byetta, Bydureon
Imipramine • Tofranil
Levomilnacipran • Fetzima
Liraglutide • Victoza, Saxenda
Lorcaserin • Belviq
Metformin • Glucophage
Methylphenidate • Ritalin, Methylin
Mirtazapine • Remeron
Naltrexone/bupropion • Contrave
Nefazodone • Serzone
Nortriptyline • Pamelo
Olanzapine • Zyprexa
Orlistat • Xenical
Paroxetine • Paxil
Phentermine/topiramate • Qsymia
Pramlintide • Symlin
Protriptyline • Vivactil
Quetiapine • Seroquel
Trazodone • Desyrel, Oleptro
Vilazodone • Viibryd
Vortioxetine • Trintellix
Zonisamide • Zonegran

Pages

Recommended Reading

Options for treating antidepressant-induced sweating
Clinician Reviews
Passive suicidal ideation: Still a high-risk clinical scenario
Clinician Reviews
Prescriber’s guide to using 3 new antidepressants: Vilazodone, levomilnacipran, vortioxetine
Clinician Reviews